The abstract is read at the publisher; the summary is JClub's.
Lacticaseibacillus rhamnosus GG (LGG) most strongly enhances gefitinib efficacy while reducing intestinal and hepatic injury in LGG-treated mice, without changing systemic gefitinib exposure.
- Why it matters: Gefitinib benefits EGFR-mutant non-small cell lung cancer, but gastrointestinal and hepatic toxicity can restrict long-term use, creating a need for microbiota-based mitigation.
- What they did: The study tested multiple probiotic strains, used metabolomics to identify propionyl-L-carnitine, and then administered propionyl-L-carnitine to reproduce LGG’s antitumor effects; it also used a gut-liver-tumor organ-on-a-chip model.
- The result: Propionyl-L-carnitine is linked to altered mitochondrial metabolism, reduced NF-κB/IL-6 signaling, increased apoptosis, and improved gut-liver metabolic readouts, supporting LGG as a strategy to enhance response while limiting toxicity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.